<DOC>
	<DOCNO>NCT02920931</DOCNO>
	<brief_summary>A Randomized , Open-label , Single-dosing , 2X2 Crossover Study Compare Safety Pharmacokinetics BR-TND Tablet ( Tenofovir Disoproxil ) With Viread Tablet ( Tenofovir Disoproxil Fumarate ) Healthy Male Volunteers .</brief_summary>
	<brief_title>A Randomized , Open-label , Single-dosing , 2X2 Crossover Study Compare Safety Pharmacokinetics BR-TND Tablet ( Tenofovir Disoproxil ) With Viread Tablet ( Tenofovir Disoproxil Fumarate ) Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Healthy male subject , age 19 45 year screen . 2 . Body weight ≥ 55 kg within ± 20 % ideal body weight ( IBW ) ( kg ) = { height ( cm ) 100 } * 0.9 3 . No morbid symptom sign , base physical examination , innate chronic disease . 4 . Subject consider appropriate participate study investigator , base clinical laboratory test ( hematology , clinical chemistry , urinalysis ) perform accord characteristic investigational drug . 5 . Subjects must able listen understand detailed statement inform consent , willing decide participate study , follow study direction provide write informed consent . 1 . A clinically significant disease history hepatobiliary system , kidney , digestive system , respiratory system , hematooncological system , endocrine system , neuropsychiatric system , musculoskeletal system , immune system , otorhinolaryngological system cardiovascular system . 2 . A history gastrointestinal system disorder ( i.e , Crohn 's disease , ulcer , acute chronic pancreatitis ) surgery ( exclude simple appendectomy herniorrhaphy ) may affect absorption investigational drug . 3 . A history hypersensitivity investigational drug additives clinically significant hypersensitivity drug . 4 . Galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption hereditary disorder . 5 . Vital sign measure sit position meet one follow result ; systolic blood pressure &gt; 140 mmHg &lt; 100 mmHg , diastolic blood pressure &gt; 90 mmHg &lt; 60 mmHg , pulse ≥ 100 times/min . 6 . Aspartate aminotransferase ( AST ) Alanine aminotransaminase ( ALT ) &gt; 2 time upper normal limit , Total bilirubin &gt; 2 time upper normal limit . 7 . Renal disorder ( Creatinine clearance &lt; 50 mL/min , calculate CockcroftGault formula ) 8 . Positive serologic test ( RPR Ab ( VDRL ) , HBsAg , hepatitis C virus ( HCV ) Ab , anti HIV ( AIDS ) ) 9 . History drug abuse , positive drug screen test . 10 . Use inducer inhibitor metabolic enzymes drug like barbiturate . 11 . Use prescribed drug herbal remedy within 2 week , use overthecounter medication within 1 week prior first administration investigational drug , affect study safety subject discretion study investigator . 12 . Participation another clinical trial bioequivalent study within 3 month prior first administration investigational drug ( The finish time previous study day last administration study drug ) 13 . Whole blood donation within 2 month component donation within 1 month , prior first administration investigational drug , transfusion within 1 month prior first administration investigational drug . 14 . Prolonged excessive alcohol consumption ( &gt; 21 units/week , 1 unit=10g pure alcohol ) , subject abstain drink 24 hour prior hospitalization discharge . 15 . Smoking 10 cigarette per day , excessive caffeine consumption ( example : instant coffee &gt; 5 cups/day ) 16 . Subjects plan get dental treatment ( tooth extraction , orthodontic treatment , endodontic treatment etc ) selective surgery ( aesthetic surgery , LASIK , LASEK etc ) period inform consent form ( ICF ) poststudy visit , impossible postpone . 17 . Subjects judge inappropriate study investigator accord reason include clinical lab test result</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>